Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenuePayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Coya Therapeutics' Accounts Payables rose 23015.43% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 23015.43%. This contributed to the annual value of $1.6 million for FY2024, which is 3742.22% up from last year.
  • According to the latest figures from Q3 2025, Coya Therapeutics' Accounts Payables is $1.1 million, which was up 23015.43% from $931344.0 recorded in Q2 2025.
  • Coya Therapeutics' 5-year Accounts Payables high stood at $1.9 million for Q2 2024, and its period low was $237579.0 during Q2 2023.
  • Moreover, its 4-year median value for Accounts Payables was $1.1 million (2023), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Coya Therapeutics' Accounts Payables soared by 69261.09% in 2024, and later plummeted by 5054.14% in 2025.
  • Over the past 4 years, Coya Therapeutics' Accounts Payables (Quarter) stood at $1.8 million in 2022, then plummeted by 36.34% to $1.2 million in 2023, then surged by 37.42% to $1.6 million in 2024, then decreased by 30.0% to $1.1 million in 2025.
  • Its Accounts Payables stands at $1.1 million for Q3 2025, versus $931344.0 for Q2 2025 and $1.7 million for Q1 2025.